TMHC(TMHC)
TMHC
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $6.64B | $7.15B |
| Low | $6.51B | $7.08B |
| High | $6.74B | $7.22B |
| EBITDA Avg | $906M | $976M |
| Low | $889M | $966M |
| High | $920M | $985M |
| EBIT Avg | $925M | $997M |
| Low | $908M | $987M |
| High | $940M | $1.01B |
| Net Income Avg | $538M | $657M |
| Low | $532M | $637M |
| High | $544M | $676M |
| EPS Avg | $5.29 | $6.54 |
| Low | $5.28 | $6.33 |
| High | $5.40 | $6.72 |
| Analysts (Rev / EPS) | 4 / 3 | 5 / 4 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $1.78B | $1.94B | $1.39B | $1.73B | $1.85B | $2.14B |
| Low | $1.72B | $1.79B | $1.29B | $1.60B | $1.71B | $1.97B |
| High | $1.84B | $2.04B | $1.47B | $1.82B | $1.95B | $2.25B |
| EBITDA Avg | $243M | $264M | $190M | $236M | $253M | $291M |
| Low | $234M | $244M | $176M | $218M | $234M | $269M |
| High | $251M | $278M | $200M | $248M | $266M | $307M |
| EBIT Avg | $249M | $270M | $194M | $241M | $259M | $298M |
| Low | $239M | $249M | $180M | $223M | $239M | $275M |
| High | $256M | $284M | $205M | $254M | $272M | $313M |
| Net Income Avg | $140M | $165M | $112M | $149M | $176M | $216M |
| Low | $126M | $148M | $100M | $135M | $159M | $195M |
| High | $150M | $176M | $119M | $160M | $188M | $231M |
| EPS Avg | $1.44 | $1.69 | $1.14 | $1.53 | $1.81 | $2.22 |
| Low | $1.30 | $1.52 | $1.03 | $1.38 | $1.63 | $2.00 |
| High | $1.54 | $1.80 | $1.22 | $1.64 | $1.93 | $2.37 |
| Analysts (Rev / EPS) | 4 / 3 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 |